相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。An update on peptide-based therapies for type 2 diabetes and obesity
Clifford J. Bailey et al.
PEPTIDES (2023)
Multiple Medication Adherence and Related Outcomes in Community-Dwelling Older People on Chronic Polypharmacy: A Retrospective Cohort Study on Administrative Claims Data
Carlotta Franchi et al.
INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH (2022)
The Impact of Novel Anti-Diabetic Medications on CV Outcomes: A New Therapeutic Horizon for Diabetic and Non-Diabetic Cardiac Patients
Israel Mazin et al.
JOURNAL OF CLINICAL MEDICINE (2022)
Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction
Michael A. Nauck et al.
CARDIOVASCULAR DIABETOLOGY (2022)
LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept
Tamer Coskun et al.
CELL METABOLISM (2022)
LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial
Shweta Urva et al.
LANCET (2022)
Prevalence of polypharmacy and associated adverse health outcomes in adult patients with chronic kidney disease: protocol for a systematic review and meta-analysis
Ikechi G. Okpechi et al.
SYSTEMATIC REVIEWS (2021)
Phase III, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of teneligliptin monotherapy in Chinese patients with type 2 diabetes mellitus inadequately controlled with diet and exercise
Linong Ji et al.
JOURNAL OF DIABETES INVESTIGATION (2021)
Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status Results From the EMPEROR-Reduced Trial
Stefan D. Anker et al.
CIRCULATION (2021)
Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease
Deepak L. Bhatt et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure
Deepak L. Bhatt et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Drug Induced Liver Injury in Geriatric Patients Detected by a Two-Hospital Prospective Pharmacovigilance Program: A Comprehensive Analysis Using the Roussel Uclaf Causality Assessment Method
Laura Pedraza et al.
FRONTIERS IN PHARMACOLOGY (2021)
The Effect of a Comprehensive, Interdisciplinary Medication Review on Quality of Life and Medication Use in Community Dwelling Older People with Polypharmacy
Donna Bosch-Lenders et al.
JOURNAL OF CLINICAL MEDICINE (2021)
Specific features of rational pharmacotherapy in elderly patients
Dmitriy Ermakov et al.
EUROPEAN JOURNAL OF HOSPITAL PHARMACY (2021)
Persistent polypharmacy and fall injury risk: the Health, Aging and Body Composition Study
Lingshu Xue et al.
BMC GERIATRICS (2021)
Polypharmacy Management in the Older Adults: A Scoping Review of Available Interventions
M. Kurczewska-Michalak et al.
FRONTIERS IN PHARMACOLOGY (2021)
Improved postprandial glucose metabolism in type 2 diabetes by the dual glucagon-like peptide-1/glucagon receptor agonist SAR425899 in comparison with liraglutide
Michele Schiavon et al.
DIABETES OBESITY & METABOLISM (2021)
Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2.4 mg for weight management: a randomised, controlled, phase 1b trial
Lone B. Enebo et al.
LANCET (2021)
Effects of Cotadutide on Metabolic and Hepatic Parameters in Adults With Overweight or Obesity and Type 2 Diabetes: A 54-Week Randomized Phase 2b Study
Rajaa Nahra et al.
DIABETES CARE (2021)
Emerging glucagon-like peptide 1 receptor agonists for the treatment of obesity
Mathies M. Jepsen et al.
EXPERT OPINION ON EMERGING DRUGS (2021)
Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial
Julio Rosenstock et al.
LANCET (2021)
Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial
Bernhard Ludvik et al.
LANCET (2021)
Danuglipron (PF-06882961) in type 2 diabetes: a randomized, placebo-controlled, multiple ascending-dose phase 1 trial
Aditi R. Saxena et al.
NATURE MEDICINE (2021)
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
Juan P. Frias et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Polypharmacy is associated with malnutrition and activities of daily living disability among daycare facility users A cross-sectional study
Tomiyo Nakamura et al.
MEDICINE (2021)
Addressing the Challenge of Polypharmacy
Alpana Mair et al.
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, VOL 60 (2020)
Efficacy and tolerability of tirzepatide, a dual glucose-dependent insulinotropic peptide and glucagon-like peptide-1 receptor agonist in patients with type 2 diabetes: A 12-week, randomized, double-blind, placebo-controlled study to evaluate different dose-escalation regimens
Juan Pablo Frias et al.
DIABETES OBESITY & METABOLISM (2020)
Dose-response, efficacy, and safety of oral semaglutide monotherapy in Japanese patients with type 2 diabetes (PIONEER 9): a 52-week, phase 2/3a, randomised, controlled trial
Yuichiro Yamada et al.
Lancet Diabetes & Endocrinology (2020)
Impact of Glucose-Lowering Medications on Cardiovascular and Metabolic Risk in Type 2 Diabetes
Angelo Maria Patti et al.
JOURNAL OF CLINICAL MEDICINE (2020)
Population ageing and mortality during 1990-2017: A global decomposition analysis
Xunjie Cheng et al.
PLOS MEDICINE (2020)
Cardiovascular outcomes trials with incretin-based medications: a critical review of data available on GLP-1 receptor agonists and DPP-4 inhibitors
Alexandros Sachinidis et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2020)
Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure
Milton Packer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Dapagliflozin in Patients with Chronic Kidney Disease
Hiddo J. L. Heerspink et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes
George L. Bakris et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes
Christopher P. Cannon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Novel Antidiabetic Agents: Cardiovascular and Safety Outcomes
Gerasimos Siasos et al.
CURRENT PHARMACEUTICAL DESIGN (2020)
Polypharmacy Is Associated With Accelerated Deterioration of Renal Function in Cardiovascular Outpatients
Jun-ichi Sakamoto et al.
CARDIOLOGY RESEARCH (2020)
Clinical pharmacology study of ipragliflozin in Japanese patients with type 1 diabetes mellitus: A phase 2, randomized, placebo-controlled trial
Kohei Kaku et al.
DIABETES OBESITY & METABOLISM (2019)
Associations Between Polypharmacy, Symptom Burden, and Quality of Life in Patients with Advanced, Life-Limiting Illness
Yael Schenker et al.
JOURNAL OF GENERAL INTERNAL MEDICINE (2019)
Dipeptidyl peptidase-4 inhibitors and cardiovascular and renal disease in type 2 diabetes: What have we learned from the CARMELINA trial?
Nordin M. J. Hanssen et al.
DIABETES & VASCULAR DISEASE RESEARCH (2019)
PIONEER 1: Randomized Clinical Trial of the Efficacy and Safety of Oral Semaglutide Monotherapy in Comparison With Placebo in Patients With Type 2 Diabetes
Vanita R. Aroda et al.
DIABETES CARE (2019)
SGLT2 Inhibitors: Cardiovascular Benefits Beyond HbA1c-Translating Evidence into Practice
Amar Ali et al.
DIABETES THERAPY (2019)
Oral Semaglutide Versus Empagliflozin in Patients With Type 2 Diabetes Uncontrolled on Metformin: The PIONEER 2 Trial
Helena W. Rodbard et al.
DIABETES CARE (2019)
Polypharmacy in Type 2 Diabetes Mellitus: Insights from an Internal Medicine Department
Elena-Codruta Dobrica et al.
MEDICINA-LITHUANIA (2019)
SGLT2 Inhibitors: A Review of Their Antidiabetic and Cardioprotective Effects
Anastasios Tentolouris et al.
INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH (2019)
Implications of the recent CVOTs in type 2 diabetes: The right place for DPP-IV inhibitors today
Zachary T. Bloomgarden
DIABETES RESEARCH AND CLINICAL PRACTICE (2019)
Empagliflozin Reduced Mortality and Hospitalization for Heart Failure Across the Spectrum of Cardiovascular Risk in the EMPA- REG OUTCOME Trial
David Fitchett et al.
CIRCULATION (2019)
Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk The CARMELINA Randomized Clinical Trial
Julio Rosenstock et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2019)
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
S. D. Wiviott et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Glutazumab, a novel long-lasting GLP-1/anti-GLP-1R antibody fusion protein, exerts anti-diabetic effects through targeting dual receptor binding sites
Caina Li et al.
BIOCHEMICAL PHARMACOLOGY (2018)
Comparative cardiovascular outcomes in the era of novel anti-diabetic agents: a comprehensive network meta-analysis of 166,371 participants from 170 randomized controlled trials
Xiao-dong Zhuang et al.
CARDIOVASCULAR DIABETOLOGY (2018)
A comparative safety review between GLP-1 receptor agonists and SGLT2 inhibitors for diabetes treatment
Agostino Consoli et al.
EXPERT OPINION ON DRUG SAFETY (2018)
Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial
Michael E. J. Lean et al.
LANCET (2018)
Safety and Efficacy of DPP4 Inhibitor and Basal Insulin in Type 2 Diabetes: An Updated Review and Challenging Clinical Scenarios
Fernando Gomez-Peralta et al.
DIABETES THERAPY (2018)
Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial
Juan Pablo Frias et al.
LANCET (2018)
Polypharmacy in Assisted Living and Impact on Clinical Outcomes
Barbara Resnick et al.
CONSULTANT PHARMACIST (2018)
What is polypharmacy? A systematic review of definitions
Nashwa Masnoon et al.
BMC GERIATRICS (2017)
Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial
Bo Ahren et al.
LANCET DIABETES & ENDOCRINOLOGY (2017)
Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial
Christopher Sorli et al.
LANCET DIABETES & ENDOCRINOLOGY (2017)
Benefits of combination of insulin degludec and liraglutide are independent of baseline glycated haemoglobin level and duration of type 2 diabetes
H. W. Rodbard et al.
DIABETES OBESITY & METABOLISM (2016)
The epidemiology of polypharmacy
Rupert A. Payne
CLINICAL MEDICINE (2016)
Efficacy and safety of teneligliptin, a novel dipeptidyl peptidase-4 inhibitor, in Korean patients with type 2 diabetes mellitus: a 24-week multicentre, randomized, double-blind, placebo-controlled phase III trial
S. Hong et al.
DIABETES OBESITY & METABOLISM (2016)
Antidiabetic Medications and Polypharmacy
Emily P. Peron et al.
CLINICS IN GERIATRIC MEDICINE (2015)
Efficacy and Safety of Once-Weekly Dulaglutide Versus Insulin Glargine in Patients With Type 2 Diabetes on Metformin and Glimepiride (AWARD-2)
Francesco Giorgino et al.
DIABETES CARE (2015)
A novel and selective sodium-glucose cotransporter-2 inhibitor, tofogliflozin, improves glycaemic control and lowers body weight in patients with type 2 diabetes mellitus
S. Ikeda et al.
DIABETES OBESITY & METABOLISM (2015)
Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes
Jennifer B. Green et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Living too long
Guy C. Brown
EMBO REPORTS (2015)
Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement
David Moher et al.
SYSTEMATIC REVIEWS (2015)
Efficacy and safety of monotherapy with the novel sodium/glucose cotransporter-2 inhibitor tofogliflozin in Japanese patients with type 2 diabetes mellitus: a combined Phase 2 and 3 randomized, placebo-controlled, double-blind, parallel-group comparative study
Kohei Kaku et al.
CARDIOVASCULAR DIABETOLOGY (2014)
Efficacy and Safety of Dulaglutide Added Onto Pioglitazone and Metformin Versus Exenatide in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-1)
Carol Wysham et al.
DIABETES CARE (2014)
Pharmacokinetic and pharmacodynamic study of ipragliflozin in Japanese patients with type 2 diabetes mellitus: A randomized, double-blind, placebo-controlled study
Takeshi Kadokura et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2014)
Safety and efficacy of teneligliptin: a novel DPP-4 inhibitor for hemodialysis patients with type 2 diabetes
Hideo Otsuki et al.
INTERNATIONAL UROLOGY AND NEPHROLOGY (2014)
Randomized, placebo-controlled, double-blind glycemic control trial of novel sodium-dependent glucose cotransporter 2 inhibitor ipragliflozin in Japanese patients with type 2 diabetes mellitus
Atsunori Kashiwagi et al.
JOURNAL OF DIABETES INVESTIGATION (2014)
Efficacy and safety of ipragliflozin in patients with type 2 diabetes inadequately controlled on metformin: a dose-finding study
J. P. H. Wilding et al.
DIABETES OBESITY & METABOLISM (2013)
Efficacy, safety and dose-response relationship of teneligliptin, a dipeptidyl peptidase-4 inhibitor, in Japanese patients with type 2 diabetes mellitus
T. Kadowaki et al.
DIABETES OBESITY & METABOLISM (2013)
Multimorbidity in Older Adults
Marcel E. Salive
EPIDEMIOLOGIC REVIEWS (2013)
Active- and placebo-controlled dose-finding study to assess the efficacy, safety, and tolerability of multiple doses of ipragliflozin in patients with type 2 diabetes mellitus
Vivian A. Fonseca et al.
JOURNAL OF DIABETES AND ITS COMPLICATIONS (2013)
Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus
Benjamin M. Scirica et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Effects of once-daily teneligliptin on 24-h blood glucose control and safety in Japanese patients with type 2 diabetes mellitus: a 4-week, randomized, double-blind, placebo-controlled trial
T. Eto et al.
DIABETES OBESITY & METABOLISM (2012)
Dapagliflozin Monotherapy in Type 2 Diabetic Patients With Inadequate Glycemic Control by Diet and Exercise A randomized, double-blind, placebo-controlled, phase 3 trial
Ele Ferrannini et al.
DIABETES CARE (2010)
Polypharmacy and Combination Therapy in the Management of Hypertension in Elderly Patients with Co-Morbid Diabetes Mellitus
Mark A. Munger
DRUGS & AGING (2010)
Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial
Richard M. Bergenstal et al.
LANCET (2010)
Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study
Daniel J. Drucker et al.
LANCET (2008)
分享论文
